Baracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety

Baracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety

Do Young Kim,1 Ju Hyun Kim,2 Won Young Tak,3 Jong Eun Yeon,4 Joon Hyeok Lee,5 Jung Hwan Yoon,6 Youn Jae Lee,7 Byung Seok Lee,8 Byung Hoon Han,9 Han Chu Lee10 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 2Department of Gastroenterology, Gachon University Gil Medica...

Full description

Bibliographic Details
Main Authors: Kim DY, Kim JH, Tak WY, Yeon JE, Lee JH, Yoon JH, Lee YJ, Lee BS, Han BH, Lee HC
Format: Article
Language:English
Published: Dove Medical Press 2017-10-01
Series:Drug Design, Development and Therapy
Subjects:
chronic hepatitis B
generic
ETV from Dong-A ST (Baracle®)
Online Access:https://www.dovepress.com/baraclereg-vs-baracludereg-for-48-weeks-in-patients-with-treatment-nai-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/baraclereg-vs-baracludereg-for-48-weeks-in-patients-with-treatment-nai-peer-reviewed-article-DDDT

Similar Items